EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antitumor Activities of Chimeric Anti-EphA2 Antibodies in Xenograft Models of Breast, Pancreatic, and Colorectal Cancers

Guanjie Li iD, Hiroyuki Suzuki iD, Tomokazu Ohishi iD, Hiroyuki Satofuka iD, Kenichiro Ishikawa, Kai Shimizu, Airi Nomura, Haruto Araki, Naoki Kojo, Kaito Suzuki, Saori Handa, Takuro Nakamura und 4 weitere

International Journal of Molecular Sciences · 02.04.2026 · 27 (7) · 3221

DOI: 10.3390/ijms27073221 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 02.04.2026. Verfasst von Guanjie Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan. Hauptthemen laut MEDLINE: Receptor, EphA2, Colorectal Neoplasms, Antibodies, Monoclonal, Pancreatic Neoplasms. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Erythropoietin-producing hepatocellular receptor A2 (EphA2) has emerged as a key mediator that promotes tumor malignant progression. EphA2 overexpression and its non-canonical signaling lead to oncogenic transformation, metabolic reprogramming, resistance to treatments, and metastasis. Therefore, strategies targeting EphA2 have been evaluated in clinical trials. However, the clinical effects were not sufficient. An anti-EphA2 monoclonal antibody (mAb), Ea2Mab-7 (mouse IgG1, κ), demonstrated high affinity and specificity among Eph receptors. In this study, we produced recombinant class-switched Ea2Mab-7 variants, including Ea2Mab-7-mG2a (mouse IgG2a) and Ea2Mab-7-hG1 (human IgG1). Both Ea2Mab-7-mG2a and Ea2Mab-7-hG1 recognized human triple-negative breast cancer MDA-MB-231, pancreatic cancer MIA PaCa-2, and colorectal cancer HCT-15 in flow cytometry. Furthermore, both Ea2Mab-7-mG2a and Ea2Mab-7-hG1 exerted significant antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against these tumors. In mouse xenograft models of breast, pancreatic, and colorectal cancers, both mAbs demonstrated antitumor activity. These results indicate the potential of Ea2Mab-7 variants for the treatment of EphA2-positive cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, EphA2Colorectal NeoplasmsAntibodies, MonoclonalPancreatic NeoplasmsBreast NeoplasmsAntineoplastic Agents, ImmunologicalAnimalsHumansFemaleMiceXenograft Model Antitumor AssaysCell Line, TumorAntibody-Dependent Cell Cytotoxicity

Stichwörter der Autor:innen

ADCCCDCEphA2breast cancercolorectal cancermonoclonal antibody therapypancreatic cancer

Substanzen

Receptor, EphA2Antibodies, MonoclonalEPHA2 protein, humanAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
  • Institute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology, Microbial Chemistry Research Foundation, 3-14-23 Kamiosaki, Shinagawa-ku, Tokyo 141-0021, Japan.

ORCID-Profile: Guanjie Li, Hiroyuki Suzuki, Tomokazu Ohishi, Hiroyuki Satofuka, Mika K Kaneko, Yukinari Kato

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research
  • Japan Society for the Promotion of Science

Zitieren

APA

Li, G., Suzuki, H., Ohishi, T., Satofuka, H., Ishikawa, K., Shimizu, K., Nomura, A., Araki, H., Kojo, N., Suzuki, K., Handa, S., Nakamura, T., Yanaka, M., Tanaka, T., Kaneko, M. K., & Kato, Y. (2026). Antitumor Activities of Chimeric Anti-EphA2 Antibodies in Xenograft Models of Breast, Pancreatic, and Colorectal Cancers. International Journal of Molecular Sciences, 27(7), 3221. https://doi.org/10.3390/ijms27073221

Vancouver

Li G, Suzuki H, Ohishi T, Satofuka H, Ishikawa K, Shimizu K, et al. Antitumor Activities of Chimeric Anti-EphA2 Antibodies in Xenograft Models of Breast, Pancreatic, and Colorectal Cancers. International Journal of Molecular Sciences. 2026;27(7):3221. doi:10.3390/ijms27073221

BibTeX
@article{Li2026,
  author = {Li, Guanjie and Suzuki, Hiroyuki and Ohishi, Tomokazu and Satofuka, Hiroyuki and Ishikawa, Kenichiro and Shimizu, Kai and Nomura, Airi and Araki, Haruto and Kojo, Naoki and Suzuki, Kaito and Handa, Saori and Nakamura, Takuro and Yanaka, Miyuki and Tanaka, Tomohiro and Kaneko, Mika K and Kato, Yukinari},
  title = {Antitumor Activities of Chimeric Anti-EphA2 Antibodies in Xenograft Models of Breast, Pancreatic, and Colorectal Cancers},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {7},
  pages = {3221},
  doi = {10.3390/ijms27073221}
}
Kostenlos starten →